scholarly journals Acute Hyperkalemia Paralysis in a Uremic Patient Taking Trimethropim-Sulfamethoxazole

2020 ◽  
Vol 08 (02) ◽  
pp. 123-125
Author(s):  
Hajar Elassas ◽  
Mariam Chettati ◽  
Wafaa Fadili ◽  
Inass Laouad
Keyword(s):  
Author(s):  
August Heidland ◽  
Katarina Sébekova ◽  
Markus Teschner

2014 ◽  
Vol 53 (17) ◽  
pp. 1971-1976 ◽  
Author(s):  
Su-Yan Duan ◽  
Chang-Ying Xing ◽  
Guang Yang ◽  
Ning-ning Wang ◽  
Bo Zhang
Keyword(s):  

1978 ◽  
Vol 12 (5) ◽  
pp. 268-271 ◽  
Author(s):  
Marie E. Gardner ◽  
William L. Fritz ◽  
Robert N. Hyland

Generalized convulsions developed in a uremic patient who had received massive doses of cefazolin which resulted in a measured serum level of greater than 512 mcg/ml of drug after dialysis. Pathophysiologic mechanisms which could have contributed to the symptoms are discussed. Physicians prescribing cefazolin and other cephalosporins need to be aware of this potential complication of therapy and adjust doses accordingly in renal failure.


1985 ◽  
Vol 31 (7) ◽  
pp. 1246-1246 ◽  
Author(s):  
P R Oldfield ◽  
B E Singer ◽  
P A Toseland
Keyword(s):  

2012 ◽  
Vol 2012 ◽  
pp. 1-4 ◽  
Author(s):  
Hung-Hao Lee ◽  
Po-Chao Hsu ◽  
Tsung-Hsien Lin ◽  
Wen-Ter Lai ◽  
Sheng-Hsiung Sheu

Nicorandil is an antianginal agent with nitrate-like and ATP-sensitive potassium channel activator properties. After activation of potassium channels, potassium ions are expelled out of the cells, which lead to membrane hyperpolarization, closure of voltage-gated calcium channels, and finally vasodilation. We present a uremic case suffering from repeated junctional bradycardia, especially before hemodialysis. After detailed evaluation, nicorandil was suspected to be the cause of hyperkalemia which induced bradycardia. This case reminds us that physicians should be aware of this potential complication in patients receiving ATP-sensitive potassium channel activator.


Sign in / Sign up

Export Citation Format

Share Document